


PRODUCT SPECIFICATION

| | |
|--------------------------|---|
| Product Name | Anti-CCDC134 |
| Product Number | HPA075348 |
| Gene Description | coiled-coil domain containing 134 |
| Alternative Names | FLJ22349 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Host | Rabbit |
| Antigen Sequence | GISEKDSNFQNPFKIDRTEFIPSTDPFQKALRE |
| Purification Method | Affinity purified using the PrEST antigen as affinity ligand |
| Verified Species | Human |
| Reactivity | |
| Recommended Applications | ICC-IF (Immunofluorescence) - Fixation/Permeabilization: PFA/Triton X-100 - Working concentration: 0.25-2 µg/ml |
| Characterization Data | Available at atlasantibodies.com/products/HPA075348 |
| Buffer | 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative. |
| Concentration | Lot dependent |
| Storage | Store at +4°C for short term storage. Long time storage is recommended at -20°C. |
| Notes | Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user. |

 *Product of Sweden. For research use only. Not intended for pharmaceutical development, diagnostic, therapeutic or any in vivo use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB.*

Warranty: The products supplied by Atlas Antibodies are warranted to meet stated product specifications and to conform to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to one year from date of sales for products used, handled and stored according to Atlas Antibodies AB's instructions. Atlas Antibodies AB's sole liability is limited to replacement of the product or refund of the purchase price. All products are supplied for research use only. They are not intended for medicinal, diagnostic or therapeutic use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB Rev. December 2012.